Longer transfer door-in-door-out times for endovascular therapy in AIS are associated with worse functional outcomes and complications.

TNKase is administered as a single intravenous bolus over 5 seconds. The Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase) for the treatment of acute ischemic stroke (AIS) in ...

Company to Highlight Imaging Biomarkers for Cytoprotection and Post Hoc Analysis from Phase 2 RESCUE Clinical Trial; RNS60 Led to Shorter Hospital Stays in Acute Ischemic Stroke Subjects Enrolled with ...

Please provide your email address to receive an email when new articles are posted on . Researchers engaged in a secondary analysis of the ESCAPE clinical trial in patients with acute ischemic stroke.

Please provide your email address to receive an email when new articles are posted on . TNKase is the first stroke treatment approved by the FDA in almost 30 years, the manufacturer said. It is ...

An earlier start to anticoagulation after an acute ischemic stroke for patients found to have atrial fibrillation appeared safe and possibly improved outcomes, according to the randomized ELAN trial.

Some patients with a common type of stroke benefit from a clot-busting drug given between 4.5 and 24 hours after symptoms emerged, according to a new study.

A new analysis supports the use of intravenous (IV) tenecteplase over IV alteplase (tissue plasminogen activator) for treatment of acute ischemic stroke. The analysis found that patients with ischemic ...

In a randomized, sham-controlled study published in the Journal of the American Medical Association (JAMA), researchers investigated the effect of remote ischemic conditioning (RIC) on functional ...

The growth of the acute ischemic stroke market is expected to be driven primarily by increased awareness of symptoms, advances in acute stroke care, and a robust pipeline of potential candidates such ...